A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).

Authors

Michael Morris

Michael J. Morris

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Michael J. Morris , Danny Francisco Martinez , Jeremy C. Durack , Susan F. Slovin , Daniel Costin Danila , Joseph A. O' Donoghue , Nicole Andrea Parada , Serge K. Lyashchenko , Jorge A. Carrasquillo , Shutian Ruan , Jason Stuart Lewis , Jennifer Keppler , Anna M. Wu , Victor E. Reuter , Wolfgang Weber , Howard I. Scher , Steven M. Larson , Neeta Pandit-Taskar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01923727

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 287)

DOI

10.1200/jco.2016.34.2_suppl.287

Abstract #

287

Poster Bd #

M14

Abstract Disclosures

Similar Posters

First Author: Susan F. Slovin

Poster

2024 ASCO Genitourinary Cancers Symposium

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

First Author: Ahmed M. Mahmoud

Poster

2024 ASCO Genitourinary Cancers Symposium

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Frederic Pouliot